AGÕæÈ˹ٷ½

STOCK TITAN

Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Jazz Pharmaceuticals (NASDAQ: JAZZ) has announced that Renee Gala will become the company's new President and Chief Executive Officer, effective August 11, 2025. Gala, currently serving as President and COO, will succeed co-founder Bruce Cozadd, who will retire as CEO but continue as Board Chairperson.

Gala brings over 30 years of experience and has been instrumental in Jazz's transformation since joining as CFO in March 2020. Under her leadership as COO, the company achieved nearly 90% total revenue growth through portfolio diversification and strategic business development. The appointment follows a comprehensive succession planning process where the Board evaluated both internal and external candidates.

Jazz Pharmaceuticals (NASDAQ: JAZZ) ha annunciato che Renee Gala sarà la nuova Presidente e Amministratrice Delegata dell'azienda, a partire dall'11 agosto 2025. Gala, attualmente Presidente e COO, succederà al cofondatore Bruce Cozadd, che si ritirerà dalla carica di CEO ma continuerà come Presidente del Consiglio di Amministrazione.

Gala vanta oltre 30 anni di esperienza ed è stata fondamentale nella trasformazione di Jazz da quando è entrata come CFO nel marzo 2020. Sotto la sua guida come COO, l'azienda ha raggiunto una crescita del 90% del fatturato totale grazie alla diversificazione del portafoglio e allo sviluppo strategico del business. La nomina segue un accurato processo di pianificazione della successione, durante il quale il Consiglio ha valutato candidati interni ed esterni.

Jazz Pharmaceuticals (NASDAQ: JAZZ) ha anunciado que Renee Gala será la nueva Presidenta y Directora Ejecutiva de la compañía, con efecto a partir del 11 de agosto de 2025. Gala, quien actualmente se desempeña como Presidenta y COO, sucederá al cofundador Bruce Cozadd, quien se retirará como CEO pero continuará como Presidenta de la Junta Directiva.

Gala aporta más de 30 años de experiencia y ha sido clave en la transformación de Jazz desde que se unió como CFO en marzo de 2020. Bajo su liderazgo como COO, la empresa logró un crecimiento cercano al 90% en ingresos totales mediante la diversificación del portafolio y el desarrollo estratégico del negocio. El nombramiento sigue a un proceso exhaustivo de planificación de sucesión en el que la Junta evaluó candidatos internos y externos.

Jazz Pharmaceuticals (NASDAQ: JAZZ)µç� Renee Galaê°€ 2025ë…� 8ì›� 11ì�ë¶€ë¡� 회사ì� 새로ìš� 사장 ê²� 최고경ì˜ìž�(CEO)ê°€ ë� 것ì´ë¼ê³  발표했습니다. 현재 사장 ê²� 최고운ì˜ì±…ìž„ìž�(COO)ì� Galaµç� ê³µë™ ì°½ë¦½ìž� Bruce Cozaddì� 뒤를 ì´ì–´ CEOì§ì—ì„� ì€í‡´í•˜ì§€ë§� ì´ì‚¬íš� ì˜ìž¥ì§ì€ ê³„ì† ë§¡ê²Œ ë©ë‹ˆë‹�.

Galaµç� 30ë…� ì´ìƒì� 경력ì� 보유하고 있으ë©�, 2020ë…� 3ì›� CFOë¡� 합류í•� ì´í›„ Jazzì� ë³€í˜ì— 중요í•� ì—­í• ì� 해왔습니ë‹�. COO로서 그녀ì� 리ë”ì‹� 아래 회사µç� í¬íЏí´ë¦¬ì˜� 다ê°í™”와 ì „ëžµì � 사업 개발ì� 통해 ê±°ì˜ 90%ì� ì´ìˆ˜ì� 성장ì� 달성했습니다. ì´ë²ˆ ìž„ëª…ì€ ì´ì‚¬íšŒê°€ ë‚´ë¶€ ë°� 외부 후보ë¥� í‰ê°€í•� 종합ì ì¸ 승계 ê³„íš ê³¼ì •ì� 결과입니ë‹�.

Jazz Pharmaceuticals (NASDAQ: JAZZ) a annoncé que Renee Gala deviendra la nouvelle Présidente et Directrice Générale de l'entreprise à compter du 11 août 2025. Gala, actuellement Présidente et COO, succédera au cofondateur Bruce Cozadd, qui prendra sa retraite en tant que CEO mais continuera en tant que Présidente du Conseil d'administration.

Gala apporte plus de 30 ans d'expérience et a joué un rôle clé dans la transformation de Jazz depuis son arrivée en tant que CFO en mars 2020. Sous sa direction en tant que COO, l'entreprise a réalisé une croissance de près de 90 % de son chiffre d'affaires total grâce à la diversification du portefeuille et au développement stratégique des activités. Cette nomination fait suite à un processus complet de planification de la succession, au cours duquel le Conseil a évalué des candidats internes et externes.

Jazz Pharmaceuticals (NASDAQ: JAZZ) hat bekanntgegeben, dass Renee Gala ab dem 11. August 2025 die neue Präsidentin und Chief Executive Officer des Unternehmens wird. Gala, die derzeit als Präsidentin und COO tätig ist, wird den Mitbegründer Bruce Cozadd ablösen, der als CEO zurücktritt, aber weiterhin als Vorstandsvorsitzender fungieren wird.

Gala verfügt über mehr als 30 Jahre Erfahrung und war seit ihrem Eintritt als CFO im März 2020 maßgeblich an der Transformation von Jazz beteiligt. Unter ihrer Führung als COO erzielte das Unternehmen durch Portfoliodiversifizierung und strategische Geschäftsentwicklung ein nahezu 90%iges Wachstum des Gesamtumsatzes. Die Ernennung folgt auf einen umfassenden Nachfolgeplanungsprozess, bei dem der Vorstand interne und externe Kandidaten bewertet hat.

Positive
  • Revenue growth of nearly 90% under Gala's leadership
  • Seamless leadership transition with current COO promotion maintaining continuity
  • Continued strategic guidance from former CEO as Board Chairperson
  • Strong pipeline and market-leading portfolio positioning for future growth
Negative
  • None.

Insights

Jazz's seamless CEO transition to insider Renee Gala represents continuity in strategy while positioning the company for next growth phase.

Jazz Pharmaceuticals has executed a well-planned leadership transition, appointing current President and COO Renee Gala as the next CEO effective August 11, 2025. This succession follows a comprehensive process initiated after co-founder Bruce Cozadd announced his retirement plans in December 2024. The transition bears all hallmarks of a carefully orchestrated leadership handover rather than an unexpected departure.

Ms. Gala brings substantial institutional knowledge and strategic continuity, having served as Jazz's CFO since 2020 before her promotion to President/COO in 2023. Her 30-year career spans finance, strategy, corporate development, and commercialization � critical skills for Jazz's continued evolution. Her selection after a thorough search process involving both internal and external candidates signals strong board confidence in the current strategic direction.

What's particularly noteworthy is Cozadd's continued involvement as Board Chair, providing governance continuity while stepping back from operations. This arrangement often proves advantageous during leadership transitions by balancing fresh operational perspectives with strategic continuity.

Under Gala's prior leadership roles at Jazz, the company has undergone significant diversification and achieved nearly 90% revenue growth. Her business development expertise positions Jazz to continue its transformation from a specialty pharmaceutical company into a broader biopharma player with robust R&D capabilities. The company explicitly mentions pursuing "new opportunities" both internally and through "external innovation" � suggesting continued focus on strategic acquisitions and partnerships to complement organic growth.

This leadership transition appears designed to maintain Jazz's strategic momentum while positioning the company for its next evolution phase under a leader who helped architect its current trajectory.

� Selection Follows Robust Succession Process Led by the Board �

â€� BruceÌýCozadd to Retire as CEO and Remain Chairperson of the Board of Directors â€�

DUBLIN, July 10, 2025 /PRNewswire/ -- Jazz PharmaceuticalsÌýplc (Nasdaq:ÌýJAZZ) today announced that the Jazz Board of Directors has unanimously selected Renee Gala, Jazz's President and Chief Operating Officer, as the President and Chief Executive Officer, effective August 11, 2025, when she will also join the Board. She will succeed co-founder, Chairperson and CEO Bruce Cozadd, who informed the Board in December 2024 of his intent to retire as CEO upon the identification of the Company's next leader. This appointment reflects a key milestone in the Board's long-term succession planning process and previously disclosed CEO transition.

Ms. Gala was promoted to the role of President and COO in October 2023, after having served as Executive Vice President and Chief Financial Officer of the Company since March 2020. She brings more than 30 years of experience across finance, strategy, corporate development and commercialization. In her current role, she oversees the Company's global business operations, which include commercial, medical, research and development, technical operations and quality, as well as corporate strategy. Ms. Gala has played a critical role in driving Jazz's ongoing transformation, includingÌýarchitecting a business development strategy that has diversified the Company's portfolio, driven total revenue growth of nearly 90%, built broad capabilities, and established a pipeline that has positioned the Company for value creation and sustainable growth.

"The Board conducted a thorough and thoughtful search including both internal and external candidates, and we're highly confident that Renee is exactly the right leader to build on Jazz's momentum," said Rick Winningham, Lead Independent Director. "The Board's priority was to find an exceptional leader who could not only operate the business but also serve as a catalyst in driving long-term growth at this important moment for the Company. Among a field of highly capable and qualified candidates, Renee was the clear standout, with a compelling set of experiences and skillsets, as well as a strong track record of driving high performance and change at Jazz through both corporate development and operational initiatives. The Board has a strong focus on Jazz's evolution and delivering value, and we believe Renee is ideally equipped to drive and deliver Jazz's continued success."

"I am honored to step into the CEO role and build upon Jazz's extraordinary legacy, fueled by exceptional people, a spirit of purpose and an unwavering commitment to patients," said Ms. Gala. "With a market-leading portfolio of medicines, a promising pipeline, a strong financial position and an ongoing focus on corporate development, Jazz has immense potential—and more work to be done to realize it. I look forward to continuing the important efforts underway and working with our team to pursue new opportunities—both within our portfolio and through external innovation—to drive greater value for our patients and shareholders. I want to express my deep appreciation to Bruce for his steadfast leadership over the past two decades in building an organization defined by patient-centricity and mutual respect, a foundation that will serve us well into the future. I'm grateful for the opportunity to have partnered with Bruce over the last five years and look forward to continuing to work with him and the Board in this next chapter."

"I co-founded Jazz 22 years ago and am immensely proud of our journey. From the beginning, our mission has been to work tirelessly to transform patient lives," said Mr.ÌýCozadd. "We have since grown into an innovative biopharma company with expanded commercial and scientific capabilities to drive the next phase of our evolution, and a value rich pipeline poised to reach even more patients than we ever thought possible. I am thrilled to be handing over the reins to Renee and am excited for her to lead Jazz into our next phase of growth. In her role as Jazz's CFO and then as our President and COO, Renee's leadership has been critical in Jazz's transformation into a high-growth biopharmaceutical company fueled by a strong R&D pipeline and robust commercial operations. I am confident that she will continue to further this mission as CEO, while nurturing the culture that makes Jazz such a compelling place to spend your career."

Mr.ÌýCozadd will continue to serve as Chairperson of the Board, providing strategic input as the Company continues to execute on its growth strategy.

About ReneeÌýGala
Ms. Gala, who joined Jazz as CFO in 2020 and was promoted to COO in 2023, is a proven organizational leader with decades of progressive leadership experience across key areas spanning finance, strategy, corporate development, and commercial at a range of life science companies. Before joining Jazz in 2020, Ms. Gala served as the CFO of GRAIL Inc., a healthcare company focused on early cancer detection. From 2014 to 2019, she served as senior vice president and CFO of Theravance Biopharma, Inc., a biopharmaceutical company, following its spin-out from Theravance, Inc. (now Innoviva, Inc.). Ms. Gala joined Theravance in 2006 and held various roles in the finance organization before leading the company's spin-out transaction. Prior to that, she served in various roles in global treasury, pharmaceutical sales and corporate strategy/business development at Eli Lilly and Company from 2001 to 2006. She also currently serves on the Board of Directors of DexCom, and previously served on the Board of Directors of Gossamer Bio, Corcept Therapeutics and Gyroscope Therapeutics, prior to its acquisition by Novartis. She holds a B.S. in Mathematics fromÌýVanderbilt UniversityÌýand an M.B.A. fromÌýColumbia Business School.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq:ÌýJAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases â€� often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered inÌýDublin, IrelandÌýwith research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visitÌýÌýfor more information.

Caution Concerning Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to: the Company's growth prospects and future financial and operating results, including the Company's expectation of future value creation and sustainable growth; the Company's expectations with respect to the transition of the CEO role; and other statements that are not historical facts. These forward-looking statements are based on the Company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties.

Actual results and the timing of events could differ materially from those anticipated in such forward- looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: maintaining or increasing sales of, and revenue from, Xywav, Rylaze and Epidiolex/Epidyolex and other marketed products; the introduction of new products into the U.S. market that compete with, or otherwise disrupt the market for the Company's products and product candidates; effectively launching and commercializing the Company's other products and product candidates; the successful completion of development and regulatory activities with respect to the Company's product candidates, obtaining and maintaining adequate coverage and reimbursement for the Company's products; the time-consuming and uncertain regulatory approval process, including the risk that the Company's current and/or planned regulatory submissions may not be submitted, accepted or approved by applicable regulatory authorities in a timely manner or at all; the costly and time-consuming pharmaceutical product development and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients; global economic, financial, and healthcare system disruptions and the current and potential future negative impacts to the Company's business operations and financial results; geopolitical events, including international tariffs and trade restrictions and the conflict between Russia and Ukraine and related sanctions; macroeconomic conditions, including global financial markets, rising interest rates and inflation and recent and potential banking disruptions; regulatory initiatives and changes in tax laws; market volatility; protecting and enhancing the Company's intellectual property rights and the Company's commercial success being dependent upon the Company obtaining, maintaining and defending intellectual property protection and exclusivity for its products and product candidates; delays or problems in the supply or manufacture of the Company's products and product candidates; complying with applicable U.S. and non-U.S. regulatory requirements, including those governing the research, development, manufacturing and distribution of controlled substances; government investigations, legal proceedings and other actions; identifying and consummating corporate development transactions, financing these transactions and successfully integrating acquired product candidates, products and businesses, including Chimerix and the acquired product candidate dordaviprone; the Company's ability to realize the anticipated benefits of its corporate development transactions and its collaborations and license agreements with third parties; the sufficiency of the Company's cash flows and capital resources; the Company's ability to achieve targeted or expected future financial performance and results and the uncertainty of future tax, accounting and other provisions and estimates; fluctuations in the market price and trading volume of the Company's ordinary shares; the timing and availability of alternative investment opportunities; the Company's ability to attract, maintain and motivate members of its executive management team and key personnel; and other risks and uncertainties affecting the Company, including those described from time to time under the caption "Risk Factors" and elsewhere in the Company's Securities and Exchange Commission filings and reports, including the Company's Annual Report on Form 10-K for the year ended December 31, 2024, the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, and future filings and reports by the Company. Other risks and uncertainties of which the Company is not currently aware may also affect the Company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated.

Contacts:
Investors:
Jack Spinks
Senior Director, Investor Relations
Jazz Pharmaceuticals plc
[email protected]
IrelandÌý+353 1 634 3211
U.S.Ìý+1 650 496 2717

Media:
Kristin Bhavnani
Head ofÌýGlobal Corporate Communications
Jazz Pharmaceuticals plc
[email protected]
IrelandÌý+353 1 637 2141
U.S. +1 215 867 4948

Cision View original content to download multimedia:

SOURCE Jazz Pharmaceuticals plc

FAQ

When will Renee Gala become CEO of Jazz Pharmaceuticals (NASDAQ: JAZZ)?

Renee Gala will assume the role of President and CEO of Jazz Pharmaceuticals on August 11, 2025.

What is Bruce Cozadd's new role at Jazz Pharmaceuticals?

Bruce Cozadd will retire as CEO but continue to serve as Chairperson of the Board, providing strategic input for the company's growth strategy.

What is Renee Gala's experience at Jazz Pharmaceuticals?

Gala has served as President and COO since October 2023, and previously as CFO since March 2020. She has over 30 years of experience across finance, strategy, corporate development and commercialization.

How has Jazz Pharmaceuticals performed under Renee Gala's leadership?

Under Gala's leadership, Jazz achieved nearly 90% total revenue growth through portfolio diversification and strategic business development initiatives.

Who led the CEO selection process for Jazz Pharmaceuticals?

The Jazz Board of Directors conducted a thorough search of both internal and external candidates, led by Lead Independent Director Rick Winningham.
Jazz Pharmaceuticals Plc

NASDAQ:JAZZ

JAZZ Rankings

JAZZ Latest News

JAZZ Latest SEC Filings

JAZZ Stock Data

6.65B
58.66M
3.09%
99.91%
7.19%
Biotechnology
Pharmaceutical Preparations
Ireland
DUBLIN